DAVITA INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
DAVITA INC. (DVA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $104.34 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-11
- DAVITA INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $104.34M, a 67.77% decline from fiscal 2024.
- DAVITA INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $323.68M, a 92.10% increase from fiscal 2023.
- DAVITA INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $168.50M, a 12.75% increase from fiscal 2022.
- DAVITA INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $149.44M, a 28.35% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|
| 2025-12-31 | $104.34M 10-K · filed 2026-02-11 | |
| 2024-12-31 | $323.68M 10-K · filed 2026-02-11 | |
| 2023-12-31 | $168.50M 10-K · filed 2026-02-11 | |
| 2022-12-31 | $149.44M 10-K · filed 2025-02-13 | |
| 2021-12-31 | $208.59M 10-K · filed 2024-02-14 | |
| 2020-12-31 | $49.26M 10-K · filed 2023-02-22 | |
| 2019-12-31 | $11.47M 10-K · filed 2022-02-11 | |
| 2018-12-31 | $31.05M 10-K · filed 2021-02-12 | |
| 2017-12-31 | $34.90M 10-K · filed 2020-02-21 | |
| 2016-12-31 | $73.94M 10-K · filed 2019-02-22 | $73.00M 10-K · filed 2017-02-24 |
| 2015-12-31 | $117.26M 10-K · filed 2018-02-23 | $116.93M 10-K · filed 2016-02-26 |
| 2014-12-31 | $151.34M 10-K · filed 2017-02-24 | |
| 2013-12-31 | $120.78M 10-K · filed 2016-02-26 | |
| 2012-12-31 | $228.70M 10-K · filed 2015-02-26 | |
| 2011-12-31 | $98.23M 10-K · filed 2014-02-21 | |
| 2010-12-31 | $67.94M 10-K · filed 2013-03-01 | |
| 2009-12-31 | $46.90M 8-K · filed 2012-07-06 | |
| 2008-12-31 | $35.96M 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |